Annual Non Current Assets
$686.33 M
-$72.50 M-9.55%
December 1, 2024
Summary
- As of March 13, 2025, RARE annual long term assets is $686.33 million, with the most recent change of -$72.50 million (-9.55%) on December 1, 2024.
- During the last 3 years, RARE annual non current assets has risen by +$20.54 million (+3.09%).
- RARE annual non current assets is now -9.55% below its all-time high of $758.83 million, reached on December 31, 2023.
Performance
RARE Non Current Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Non Current Assets
$686.33 M
-$52.42 M-7.10%
December 1, 2024
Summary
- As of March 13, 2025, RARE quarterly long term assets is $686.33 million, with the most recent change of -$52.42 million (-7.10%) on December 1, 2024.
- Over the past year, RARE quarterly non current assets has dropped by -$72.50 million (-9.55%).
- RARE quarterly non current assets is now -9.55% below its all-time high of $758.83 million, reached on December 31, 2023.
Performance
RARE Quarterly Non Current Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Non Current Assets Formula
Non Current Assets = Property, Plant, and Equipment + Intangible Assets + Long-Term Investments + Deferred Tax Assets + Other Non-Current Assets
RARE Non Current Assets Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -9.6% | -9.6% |
| 3 y3 years | +3.1% | +3.1% |
| 5 y5 years | +141.3% | +141.3% |
RARE Non Current Assets Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -9.6% | +3.8% | -9.6% | +13.3% |
| 5 y | 5-year | -9.6% | +141.3% | -9.6% | +141.3% |
| alltime | all time | -9.6% | >+9999.0% | -9.6% | >+9999.0% |
Ultragenyx Pharmaceutical Non Current Assets History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $745.03 M(+1.8%) | $686.33 M(-7.1%) |
| Sep 2024 | - | $738.75 M(+13.0%) |
| Jun 2024 | - | $653.80 M(-8.1%) |
| Mar 2024 | - | $711.11 M(-6.3%) |
| Dec 2023 | $732.18 M(-17.2%) | $758.83 M(+18.8%) |
| Sep 2023 | - | $638.95 M(+4.9%) |
| Jun 2023 | - | $609.17 M(-1.3%) |
| Mar 2023 | - | $617.07 M(-6.7%) |
| Dec 2022 | $883.90 M(+3.2%) | $661.54 M(+9.2%) |
| Sep 2022 | - | $605.81 M(-5.7%) |
| Jun 2022 | - | $642.09 M(-5.1%) |
| Mar 2022 | - | $676.51 M(+1.6%) |
| Dec 2021 | $856.60 M(-33.9%) | $665.79 M(+4.4%) |
| Sep 2021 | - | $637.92 M(+13.3%) |
| Jun 2021 | - | $562.95 M(+6.9%) |
| Mar 2021 | - | $526.83 M(+13.5%) |
| Dec 2020 | $1.30 B(+52.2%) | $464.25 M(+17.1%) |
| Sep 2020 | - | $396.38 M(-2.8%) |
| Jun 2020 | - | $408.00 M(+20.4%) |
| Mar 2020 | - | $338.82 M(+19.1%) |
| Dec 2019 | $851.02 M(+62.9%) | $284.48 M(+6.8%) |
| Sep 2019 | - | $266.46 M(+2.7%) |
| Jun 2019 | - | $259.50 M(+17.5%) |
| Mar 2019 | - | $220.87 M(+12.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $522.37 M(+93.8%) | $197.19 M(-0.2%) |
| Sep 2018 | - | $197.66 M(-1.8%) |
| Jun 2018 | - | $201.28 M(-14.6%) |
| Mar 2018 | - | $235.77 M(+6.6%) |
| Dec 2017 | $269.58 M(-32.9%) | $221.17 M(+401.0%) |
| Sep 2017 | - | $44.14 M(-43.2%) |
| Jun 2017 | - | $77.75 M(-23.1%) |
| Mar 2017 | - | $101.14 M(-27.2%) |
| Dec 2016 | $401.69 M(-10.8%) | $138.93 M(+41.2%) |
| Sep 2016 | - | $98.38 M(+38.8%) |
| Jun 2016 | - | $70.87 M(-24.6%) |
| Mar 2016 | - | $93.95 M(-14.1%) |
| Dec 2015 | $450.21 M(+132.8%) | $109.36 M(-22.7%) |
| Sep 2015 | - | $141.42 M(+2084.5%) |
| Jun 2015 | - | $6.47 M(+21.6%) |
| Mar 2015 | - | $5.33 M(+17.0%) |
| Dec 2014 | $193.42 M(+250.2%) | $4.55 M(+8.6%) |
| Sep 2014 | - | $4.19 M(-4.1%) |
| Jun 2014 | - | $4.37 M(+42.3%) |
| Mar 2014 | - | $3.07 M(-30.6%) |
| Dec 2013 | $55.23 M(-36.1%) | $4.42 M(+130.8%) |
| Sep 2013 | - | $1.92 M(+2.5%) |
| Dec 2012 | $86.44 M(+689.2%) | $1.87 M |
| Dec 2011 | $10.95 M | - |
FAQ
- What is Ultragenyx Pharmaceutical annual long term assets?
- What is the all time high annual non current assets for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual non current assets year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly long term assets?
- What is the all time high quarterly non current assets for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly non current assets year-on-year change?
What is Ultragenyx Pharmaceutical annual long term assets?
The current annual non current assets of RARE is $686.33 M
What is the all time high annual non current assets for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual long term assets is $758.83 M
What is Ultragenyx Pharmaceutical annual non current assets year-on-year change?
Over the past year, RARE annual long term assets has changed by -$72.50 M (-9.55%)
What is Ultragenyx Pharmaceutical quarterly long term assets?
The current quarterly non current assets of RARE is $686.33 M
What is the all time high quarterly non current assets for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly long term assets is $758.83 M
What is Ultragenyx Pharmaceutical quarterly non current assets year-on-year change?
Over the past year, RARE quarterly long term assets has changed by -$72.50 M (-9.55%)